Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VMT01
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Viewpoint Molecular Targeting
Deal Size : Undisclosed
Deal Type : Merger
Details : The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
June 02, 2023
Lead Product(s) : VMT01
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Viewpoint Molecular Targeting
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Cesium-131
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : University of Cincinnati
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2020
Lead Product(s) : Cesium-131
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : University of Cincinnati
Deal Size : Inapplicable
Deal Type : Inapplicable